Navelbine (Vinorelbine Tartrate)

• Vinorelbine is a chemotherapy agent used in the management of solid tumours, particularly within the lung and breast cancer pathways.
• Non‑small cell lung cancer: helps to inhibit tumour growth and improve disease control in advanced stages.
• Metastatic breast cancer: used to reduce tumour progression and extend survival.
• Combination chemotherapy regimens: incorporated to enhance antitumour activity when used with other cytotoxic agents in various solid tumours.

• Vinorelbine binds to tubulin, preventing its polymerisation into microtubules. This inhibition disrupts the formation of the mitotic spindle, arresting cells in the M phase of the cell cycle and ultimately leading to apoptosis of rapidly dividing cancer cells.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Nausea and vomiting: gastrointestinal upset commonly reported.
• Constipation: decreased bowel motility.
• Alopecia: hair loss during treatment.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection: potentially life‑threatening.
• Hypersensitivity reactions: including rash, bronchospasm, or anaphylaxis.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Peripheral neuropathy: nerve damage causing tingling or pain.
• Cardiac arrhythmias: irregular heart rhythms requiring monitoring.

• Vinorelbine requires careful monitoring and specific safety measures before and during therapy.
• Monitor blood counts: perform regular complete blood counts to detect myelosuppression.
• Assess liver function: evaluate hepatic enzymes as the drug is metabolised hepatically.
• Evaluate pulmonary status: use caution in patients with pre‑existing lung disease.
• Avoid in severe renal impairment: dose adjustment may be necessary.
• Use with caution when combined with other myelosuppressive agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase vinorelbine plasma levels.
• Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk.